CXCR3 antagonism impairs the development of donor-reactive, IFN-γ-producing effectors and prolongs allograft survival

Transplantation

Volumn 87, Issue 3, 2009, Pages 360-369

  Rosenblum, Joshua M ^a,b   Zhang, Qi Wei ^b   Siu, Gerald ^c   Collins, Tassie L ^c   Sullivan, Timothy ^c   Dairaghi, Daniel J ^d   Medina, Julio C ^c   Fairchild, Robert L ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c AMGEN INC   (United States)

^d ChemoCentryx Inc   (United States)

Author keywords

Acute rejection; Chemokine receptor antagonists; Chemokines; IFN

Indexed keywords

AMG 1237845; CD40 LIGAND MONOCLONAL ANTIBODY; CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; OKT 8; UNCLASSIFIED DRUG; CXCR3 PROTEIN, MOUSE;

ACUTE GRAFT REJECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC GRAFT REJECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; GRAFT SURVIVAL; HEART TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LEUKOCYTE; LIGAND BINDING; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN; A J MOUSE; ALLOTRANSPLANTATION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; DRUG ANTAGONISM; GRAFT REJECTION; HETEROTOPIC TRANSPLANTATION; IMMUNOLOGY;

ANIMALS; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; MICE; MICE, INBRED A; MICE, INBRED BALB C; MICE, INBRED C57BL; RECEPTORS, CXCR3; TRANSPLANTATION, HETEROTOPIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 61849120801     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31819574e9     Document Type: Article

References (41)

1. Hall BM, Dorsch SE. Cells mediating allograft rejection. Immunol Rev 1984; 77: 31.
2. Hayry P, von Willebrand E, Parthenais E, et al. The inflammatory mechanisms of allograft rejection. Immunol Rev 1984; 77: 85.
3. Koga S, Auerbach MB, Engeman TM, et al. T cell infiltration into class II MHC-disparate allografts and acute rejection is dependent on the IFN-gamma-induced chemokine Mig. J Immunol 1999; 163: 4878.
4. Miura M, Morita K, Kobayashi H, et al. Monokine induced by IFN-gamma is a dominant factor directing T cells into murine cardiac allo-grafts during acute rejection. J Immunol 2001; 167: 3494.
5. Agostini C, Calabrese F, Rea F, et al. Cxcr3 and its ligand CXCL10 are expressed byinflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection. Am J Pathol 2001; 158: 1703.
6. Hancock WW, Gao W, Csizmadia V, et al. Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med 2001; 193: 975.
7. El-Sawy T, NM Fahmy, RL Fairchild. Chemokines: Directing leukocyte infiltration into allografts. Curr Opin Immunol 2002; 14: 562.
8. Hancock WW. Chemokine receptor-dependent alloresponses. Immunol Rev 2003; 196: 37.
9. Fahmy NM, Yamani MH, Starling RC, et al. Chemokine and receptor-gene expression during early and late acute rejection episodesinhuman cardiac allografts. Transplantation 2003; 75: 2044.
10. Fahmy NM, Yamani MH, Starling RC, et al. Chemokine and chemo-kine receptor gene expression indicates acute rejection of human cardiac transplants. Transplantation 2003; 75: 72.
11. Fairchild RL, VanBuskirk AM, Kondo T, et al. Expression of chemo-kine genes during rejection and long-term acceptance of cardiac allo-grafts. Transplantation 1997; 63: 1807.
12. Kondo T, Novick AC, Toma H, et al. Induction of chemokine gene expression during allogeneic skin graft rejection. Transplantation 1996; 61: 1750.
13. Melter M, Exeni A, Reinders ME, et al. Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection. Circulation 2001; 104: 2558.
14. Nozaki T, Amano H, Bickerstaff A, et al. Antibody-mediated rejection of cardiac allografts inCCR5-deficient recipients. J Immunol 2007; 179: 5238.
15. Ajithkumar TV, Parkinson CA, Butler A, et al. Management of solid tumours in organ-transplant recipients. Lancet Oncol 2007; 8: 921.
16. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357: 2601.
17. Hancock WW, Lu B, Gao W, et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 2000; 192: 1515.
18. Baker MS, Chen X, Rotramel AR, et al. Genetic deletion of chemokine receptor CXCR3 or antibody blockade of its ligand IP-10 modulates posttransplantation graft-site lymphocytic infiltrates and prolongs functional graft survival in pancreatic islet allograft recipients. Surgery 2003; 134: 126.
19. DuffnerU,Lu B, Hildebrandt GC, et al. RoleofCXCR3-induced donor T-cell migration in acute GVHD. Exp Hematol 2003; 31: 897.
20. Zhang Z, Kaptanoglu L, Tang Y, et al. IP-10-induced recruitment of CXCR3 host T cells is required for small bowel allograft rejection. Gastroenterology 2004; 126: 809.
21. Kwun J, Hazinedaroglu SM, Schadde E, et al. Unaltered graft survival and intragraft lymphocytes infiltration in the cardiac allograft of Cxcr3-/- mouse recipients. Am J Transplant 2008; 8: 1593.
22. Zerwes HG, Li J, Kovarik J, et al. The chemokine receptor Cxcr3 is not essential for acute cardiac allograft rejection in mice and rats. Am J Transplant 2008; 8: 1604.
23. Uppaluri R, Sheehan KC, Wang L, et al. Prolongation of cardiac and islet allograft survival by a blocking hamster anti-mouse CXCR3 monoclonal antibody. Transplantation 2008; 86: 137.
24. Johnson M, Li AR, Liu J, et al. Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3. Bioorg Med Chem Lett 2007; 17: 3339.
25. Corry RJ, Winn HJ, Russell PS. Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation 1973; 16: 343.
26. Afanasyeva M, Georgakopoulos D, Belardi DF, et al. Quantitative analysis of myocardial inflammation by flow cytometry in murine autoimmune myocarditis: Correlation with cardiac function. Am J Pathol 2004; 164: 807.
27. Liu L, Callahan MK, Huang D, et al. Chemokine receptor CXCR3: An unexpected enigma. Curr Top Dev Biol 2005; 68: 149.
28. Lu B, Humbles A, Bota D, et al. Structure and function of the murine chemokine receptor CXCR3. EurJ Immunol 1999; 29: 3804.
29. Qin S, Rottman JB, Myers P, et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998; 101: 746.
30. Dufour JH, Dziejman M, Liu MT, et al. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 2002; 168: 3195.
31. Walser TC, Rifat S, Ma X, et al. Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res 2006; 66: 7701.
32. Kwun J, Hu H, Schadde E, et al. Altered distribution of H60 minor H antigen-specific CD8 T cells and attenuated chronic vasculopathy in minor histocompatibility antigen mismatched heart transplantation in Cxcr3-/- mouse recipients. JImmunol 2007; 179: 8016.
33. Hidalgo LG, Halloran PF. Role of IFN-gamma in allograft rejection. Crit Rev Immunol 2002; 22: 317.
34. Pirenne J, Pirenne-Noizat F, de Groote D, et al. Cytokines and organ transplantation. Areview. Nucl Med Biol 1994; 21: 545.
35. Campbell JD, Gangur V, Simons FE, et al. Allergic humans are hypo-responsive to a CXCR3 ligand-mediated Th1 immunity-promoting loop. FASEB J 2004; 18: 329.
36. Gangur V, Simons FE, Hayglass KT. Human IP-10 selectively promotes dominance of polyclonally activated and environmental antigen-driven IFN-gamma over IL-4 responses. FASEB J 1998; 12: 705.
37. Akashi S, Sho M, Kashizuka H, et al. A novel small-molecule compound targeting CCR5 and CXCR3 prevents acute and chronic allograft rejection. Transplantation 2005; 80: 378.
38. Schnickel GT, Bastani S, Hsieh GR, et al. Combined CXCR3/CCR5 blockade attenuates acute and chronic rejection. J Immunol 2008; 180: 4714.
39. Hauser AE, Debes GF, Arce S, et al. Chemotactic responsiveness toward ligands for CXCR3 and CXCR4 is regulated on plasma blasts during the time course ofa memory immune response. J Immunol 2002; 169:1277.
40. Muehlinghaus G, Cigliano L, Huehn S, et al. Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells. Blood 2005; 105: 3965.
41. Tsubaki T, Takegawa S, Hanamoto H, et al. Accumulation of plasma cells expressing CXCR3 in the synovial sublining regions of early rheumatoid arthritis in association with production of Mig/CXCL9 by synovial fibroblasts. Clin Exp Immunol 2005; 141: 363.